deltatrials
Completed PHASE3 INTERVENTIONAL 4-arm NCT03022097

Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients (AVANT)

A 24-week Treatment, Randomised, Parallel-group, Double Blinded, Double-Dummy, Multicenter Study to Assess the Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Compared With Individual Components and Placebo and Aclidinium Bromide Compared With Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.

Sponsor: AstraZeneca

Conditions COPD
Interventions Aclidinium bromide Aclidinium bromide/formoterol Fixed-Dose Combination Formoterol Fumarate Placebo
Updated 41 times since 2017 Last updated: Mar 25, 2025 Started: Feb 2, 2017 Primary completion: Apr 14, 2022 Completion: Apr 14, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03022097, this PHASE3 trial focuses on COPD and remains completed. Sponsored by AstraZeneca, it has been updated 41 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~May 2017 · 2 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Oct 2017 · 3 months · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Apr 2018 · 4 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Dec 2019 · 3 months · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Sep 2020 · 4 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Apr 2022 · 3 months · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

41 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Feb 2026 [monthly]

    Completed PHASE3

  3. Apr 2025 — Sep 2025 [monthly]

    Completed PHASE3

  4. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

▶ Show 36 earlier versions

  1. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Apr 2022 — Jun 2022 [monthly]

    Active Not Recruiting PHASE3

  3. Jan 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  4. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  5. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  6. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  7. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

    Status: Active Not Recruiting → Recruiting

  8. Apr 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE3

  9. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE3

  10. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  11. May 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  12. Feb 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  13. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE3

  14. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  15. Sep 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  16. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  17. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

  18. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

  19. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  20. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  21. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

  22. Dec 2018 — Feb 2019 [monthly]

    Recruiting PHASE3

  23. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  24. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  25. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  26. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  27. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  28. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  29. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  30. Dec 2017 — Apr 2018 [monthly]

    Recruiting PHASE3

  31. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  32. Jul 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  33. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  34. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  35. Mar 2017 — May 2017 [monthly]

    Recruiting PHASE3

  36. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Parexel
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Alappuzha, India , Baotou, China , Beijing, China , Caloocan, Philippines , Cangzhou, China , Changchun, China , Changsha, China , Chengdu, China , Ernākulam, India and 42 more locations